Page last updated: 2024-12-04

cetylpyridinium

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Cetylpyridinium chloride (CPC) is a cationic surfactant commonly used as an antiseptic and disinfectant. It is synthesized by reacting cetyl alcohol with pyridine in the presence of a catalyst. CPC is known for its broad-spectrum antimicrobial activity, effectively killing bacteria, fungi, and viruses. It is widely used in oral care products like mouthwashes and toothpastes due to its ability to reduce plaque and gingivitis. CPC is also found in topical medications for skin infections, wound care products, and some disinfectants. Its ability to disrupt bacterial cell membranes and its low toxicity make it a valuable compound for various applications. Researchers continue to study CPC for its potential in treating oral and skin infections, as well as for its antiviral properties. '

Cetylpyridinium: Cationic bactericidal surfactant used as a topical antiseptic for skin, wounds, mucous membranes, instruments, etc.; and also as a component in mouthwash and lozenges. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID2683
CHEMBL ID305906
CHEBI ID32914
SCHEMBL ID122873
MeSH IDM0003973

Synonyms (64)

Synonym
AKOS005410694
DIVK1C_000346
KBIO1_000346
SPECTRUM_000116
pyridinium, 1-hexadecyl-
hexadecylpyridinium
cetylpyridium
cetylpyridinum
brn 1431415
7773-52-6
CHEBI:32914 ,
n-hexadecylpyridinium
1-hexadecylpyridinium
BSPBIO_001969
IDI1_000346
QTL1_000018
cetylpyridinium
1-hexadecyl-pyridinium
1-hexadecylpyridin-1-ium
STK177346
KBIO2_000556
KBIOGR_000764
KBIOSS_000556
KBIO3_001189
KBIO2_005692
KBIO2_003124
NINDS_000346
SPECTRUM4_000272
SPBIO_000540
SPECTRUM2_000460
SPECTRUM3_000335
SPECTRUM5_000675
NCGC00091023-02
MLS002695907 ,
inchi=1/c21h38n/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-16-19-22-20-17-15-18-21-22/h15,17-18,20-21h,2-14,16,19h2,1h3/q+1
neusvaojnuqrtm-uhfffaoysa-
smr001398783
CHEMBL305906
D07666
cetylpyridinium (dcf)
NCGC00091023-04
NCGC00091023-05
NCGC00091023-03
unii-cub7ji0jv3
cub7ji0jv3 ,
5-20-05-00233 (beilstein handbook reference)
NEUSVAOJNUQRTM-UHFFFAOYSA-N
cetylpyridinium [who-dd]
cetylpyridinium [vandf]
cetylpyridinium ion
pyridinium, 1-hexadecyl
cetylpyridinium cation
SCHEMBL122873
DTXSID8047979
bdbm80992
1-cetylpyridin-1-ium;bromide
cid_8816
AB00053792_07
AB00053792_08
SBI-0051276.P003
DB11073
Q27115152
BRD-K87700323-003-03-6
STARBLD0000860

Research Excerpts

Effects

Cetylpyridinium chloride kills glioblastoma cells in a dose dependent manner at a higher efficacy compared to current standard of care drug, temozolomide.

ExcerptReferenceRelevance
"Cetylpyridinium chloride has been administered in humans as a safe drug-disinfectant for several decades, and we report here that under in vitro conditions, cetylpyridinium chloride kills glioblastoma cells in a dose dependent manner at a higher efficacy compared to current standard of care drug, temozolomide."( Cetylpyridinium chloride is a potent AMP-activated kinase (AMPK) inducer and has therapeutic potential in cancer.
Allen, SA; Angelastro, JM; Cortopassi, GA; Datta, S; Sandoval, J; Sears, T; Tomilov, A; Woolard, K, 2020
)
2.72
"Cetylpyridinium chloride has been shown to be an effective radiosensitizer of both oxic and anoxic suspensions of Serratia marcescens in buffer. "( Radiosensitization of Serratia marcescens by cetylpyridinium chloride. Evidence for membrane-associated events.
Patterson, LK; Redpath, JL, 1976
)
1.96

Toxicity

ExcerptReferenceRelevance
" Adverse effects were minimal, with mild peeling occurring in seven patients and erythema noted in one."( Open-label study of the safety and efficacy of Fungoid tincture in patients with distal subungual onychomycosis of the toes.
Cohen, JL; Hochman, LG; Holwell, JE; Meyerson, MS; Pappert, AS; Scher, RK, 1992
)
0.28
" CPC is orally toxic to rats, mice and rabbits and can cause severe eye irritation."( Acute inhalation toxicity of cetylpyridinium chloride.
Davidson, TJ; Lin, GH; Voss, KA, 1991
)
0.57
" There were minimal adverse effects."( A double-blind, vehicle-controlled study of the safety and efficacy of Fungoid Tincture in patients with distal subungual onychomycosis of the toes.
Montana, JB; Scher, RK, 1994
)
0.29
" Meanwhile the toxicity, in particular, the acute dermal irritation/corrosion of the sulfoniums, tended to be lower than that of common cationic antimicrobials which were toxic in many cases indices."( The antimicrobial activity, hydrophobicity and toxicity of sulfonium compounds, and their relationship.
Hirayama, M, 2011
)
0.37
" Feedback questionnaire and spectrophotometer evaluated secondary outcomes: adverse events."( Therapeutic efficacy of chlorhexidine-based mouthwashes and its adverse events: Performance-related evaluation of mouthwashes added with Anti-Discoloration System and cetylpyridinium chloride.
Corridore, D; Guerra, F; Mazur, M; Nardi, GM; Nofroni, I; Ottolenghi, L; Pasqualotto, D; Rinaldo, F, 2019
)
0.71

Compound-Compound Interactions

ExcerptReferenceRelevance
" The inhibitory effect of antibacterial agents was significantly reduced when combined with a dentin conditioner."( The antimicrobial activity of a dentin conditioner combined with antibacterial agents.
Botelho, MG,
)
0.13
"The environmental genotoxic behavior of silver nanoparticles (nanoAg) combined with the detergent cetylpyridine bromide (CPB) was examined in vitro."( A new strategy to probe the genotoxicity of silver nanoparticles combined with cetylpyridine bromide.
Chi, Z; Hao, X; Liu, R; Pan, X; Qin, P; Sun, F; Zhao, L, 2009
)
0.35

Bioavailability

ExcerptReferenceRelevance
"CPC bioavailability in a formulation without alcohol and Tween80 could be demonstrated through measures of pellicle surface properties and bacterial interactions in vitro as well as bacteriocidal actions on oral biofilms in vivo."( Surfactive and antibacterial activity of cetylpyridinium chloride formulations in vitro and in vivo.
Atema-Smit, J; Busscher, HJ; de Vries, J; Geertsema-Doornbusch, G; van der Mei, HC; White, DJ, 2008
)
0.61
" Time to lesion healing was correlated with NB-001 bioavailability determined in human cadaver skin."( Treatment with a novel topical nanoemulsion (NB-001) speeds time to healing of recurrent cold sores.
Baker, JR; Boivin, G; Ciotti, S; Flack, MR; Ijzerman, M; Jarratt, M; Jones, TM; Kircik, L; Stanberry, LR; Sutcliffe, J, 2012
)
0.38
" A CPC delivery-controlled system, transported in polymer nanofibers (PVP/PMMA), was developed to increase the bioavailability of the drug in contact with the oral mucosa."( Antifungal effect of electrospun nanofibers containing cetylpyridinium chloride against Candida albicans.
Borsatti, MA; Oliveira, AM; Santos, VA; Viera, PV; Zanin, MH, 2014
)
0.65
" Comparison of DRA to PGRM glycolysis showed a linear relation highlighting correlation of CPC bioavailability to clinical antimicrobial performance of CPC mouthrinses."( Comparative bioavailability and antimicrobial activity of cetylpyridinium chloride mouthrinses in vitro and in vivo.
Anastasia, K; Cheng, R; Coggan, J; Gabbard, M; Garcia-Godoy, F; Klukowska, MA; White, DJ; Zhang, YH, 2014
)
0.65
"Nitric Oxide (NO) bioavailability is essential for vascular health."( A stepwise reduction in plasma and salivary nitrite with increasing strengths of mouthwash following a dietary nitrate load.
Allen, JD; Smoliga, JM; Stabler, T; Tarzia, B; Van Bruggen, M; Woessner, M, 2016
)
0.43
"Adefovir is an antiviral drug that exhibits high hydrophilic properties and negligible bioavailability (less than 12%)."( Evaluation of Ion-pair Formation of Adefovir to Improve Permeation across Artificial and Biological Membranes.
Darsazan, B; Mortazavi, SA; Shafaati, A; Zarghi, A, 2018
)
0.48

Dosage Studied

ExcerptRelevanceReference
" The higher lidocaine dosage administered (21 mg) did not intensify the positive impact on the cardiovascular parameters compared to the lower dosage (14 mg)."( Effects of different lidocaine sprays for topical anesthesia on cardiovascular parameters and oxygen saturation.
Daubländer, M; Lipp, M; Roth, W, 1992
)
0.28
" This study compared chemical dosing techniques for recovery of NTM from water samples collected from 115 randomly selected dialysis centers."( Efficacy of chemical dosing methods for isolating nontuberculous mycobacteria from water supplies of dialysis centers.
Bland, LA; Carson, LA; Cusick, LB; Favero, MS, 1988
)
0.27
" A stimulation of sulphate incorporation obeying a linear dose-response curve, was demonstrated in somatomedin-incubated fibroblast and glia cell cultures."( A novel assay for the biosynthesis of sulphated polysaccharide and its application to studies on the effects of somatomedin on cultured cells.
Uthne, K; Wasteson, A; Westermark, B, 1973
)
0.25
" An alternative method, synchronous scanning fluorimetry, in which the decrease in catechol concentration was measured under standardized conditions, provided a good dose-response histogram for all the biocides tested."( Rapid evaluation of biocidal activity using a transposon-encoded catechol 2,3-dioxygenase from Pseudomonas putida.
Day, MJ; Edghill, LA; Furr, JR; Russell, AD, 1999
)
0.3
" The objective was to examine the anti-VSC dose-response effects of each of the above agents."( Inhibition of orally produced volatile sulfur compounds by zinc, chlorhexidine or cetylpyridinium chloride--effect of concentration.
Jonski, G; Rölla, G; Young, A, 2003
)
0.54
" Dose-response curves were obtained for both antiseptics."( Reduction of salivary S. aureus and mutans group streptococci by a preprocedural chlorhexidine rinse and maximal inhibitory dilutions of chlorhexidine and cetylpyridinium.
de Albuquerque, RF; Head, TW; Ito, IY; Mian, H; Müller, K; Rodrigo, A; Sanches, K, 2004
)
0.52
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pyridinium ion
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency0.44970.000811.382244.6684AID686978; AID686979
Smad3Homo sapiens (human)Potency12.58930.00527.809829.0929AID588855
67.9K proteinVaccinia virusPotency13.35730.00018.4406100.0000AID720579; AID720580
flap endonuclease 1Homo sapiens (human)Potency100.00000.133725.412989.1251AID588795
Alpha-synucleinHomo sapiens (human)Potency14.12540.56239.398525.1189AID652106
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
interferon gamma precursorHomo sapiens (human)AC509.17500.128015.173038.6100AID1259418; AID1259420
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (77)

Processvia Protein(s)Taxonomy
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (26)

Processvia Protein(s)Taxonomy
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (22)

Processvia Protein(s)Taxonomy
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID61002The maximum dopamine release induced by perfusion with the test compound with basal striatal DA (%of basal x10E-3)1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
In vivo intracerebral microdialysis studies in rats of MPP+ analogues and related charged species.
AID61001The maximal DA release induced by perfusion with 10 mM MPP+ (15 min) 1 day after perfusion with the test compound with basal striatal DA (%of basal x10E-3)1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
In vivo intracerebral microdialysis studies in rats of MPP+ analogues and related charged species.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (960)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990254 (26.46)18.7374
1990's135 (14.06)18.2507
2000's214 (22.29)29.6817
2010's270 (28.13)24.3611
2020's87 (9.06)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 62.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index62.84 (24.57)
Research Supply Index7.10 (2.92)
Research Growth Index4.65 (4.65)
Search Engine Demand Index135.17 (26.88)
Search Engine Supply Index2.47 (0.95)

This Compound (62.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials178 (17.32%)5.53%
Reviews29 (2.82%)6.00%
Case Studies10 (0.97%)4.05%
Observational1 (0.10%)0.25%
Other810 (78.79%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (29)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Single-arm, Open-label Study to Explore the Salivary Concentration of Cetylpyridinium Chloride Buccal Tablets After Single-dose Administration in Healthy Subjects [NCT05802628]Phase 410 participants (Actual)Interventional2023-04-10Completed
A Phase I Study of a Novel Mouthwash Formulation (Cetylpyridinium Chloride 0.05% + Benzydamine HCl 0.15% + Mucus - Adhesive Polymer) Administered Twice a Day for 7 Days to Healthy Subjects in Comparison With Marketed Tantum Verde Bocca Mouthwash Solution [NCT03706781]Phase 126 participants (Actual)Interventional2017-11-14Completed
Randomized, Double Blinded, Placebo-controlled Trial to Assess the Preventive Effects of Cetylpyridinium Chloride on Sarcopenia: An Exploratory Pilot Study [NCT02297997]Early Phase 165 participants (Actual)Interventional2014-11-13Completed
Antiviral Efficacy and Acceptability of Therapeutic Antiseptic Mouth Rinses for Inactivation of COVID SARS-2 Virus [NCT04584684]Phase 2129 participants (Actual)Interventional2020-12-18Terminated(stopped due to The team decided to terminate the trial in order to start a new trial, unrelated to safety reasons)
Antiviral Efficacy of Oral Rinses for Inactivation of COVID-19 (MOR2) [NCT05178173]150 participants (Anticipated)Interventional2022-01-20Recruiting
Randomized, Double Blinded, Placebo-controlled Trial to Assess the Preventive Effects of Cetylpyridinium Chloride on Sarcopenia [NCT02575235]Early Phase 1100 participants (Actual)Interventional2015-10-01Completed
Single Site Study, Phase III, for Safety Dermatological Evaluation: Basic Acceptability With Odontological Follow up - Cepacol Teen. [NCT00729599]Phase 331 participants (Actual)Interventional2008-07-31Completed
Effect of Antiseptic Mouthwash/Gargling Solutions and Pre-procedural Rinse on SARS-CoV-2 Load (COVID-19) [NCT04409873]Phase 254 participants (Actual)Interventional2021-03-31Terminated(stopped due to The funder decided not to continue funding, causing enrollment to cease prematurely and curtailing originally planned analyses. Participants with any samples collected after the baseline pre-rinse samples were included in the analysis.)
Mouth Rinses Efficacy on Salivary SARS-CoV-2 Viral Load: A Randomized Clinical Trial [NCT04721457]Phase 490 participants (Actual)Interventional2021-01-03Completed
Uni Centric Study, Phase III, for Safety Oral Mucosa Evaluation: Basic Acceptability With Odontological Follow up - Cepacol Canela Power [NCT00687037]Phase 330 participants (Actual)Interventional2008-01-31Completed
Feasibility and Acceptability of Daily Oral Rinse in Pregnant Women and Impact on Oral Inflammatory Biomarkers in Rural Nepal [NCT02788786]Phase 2175 participants (Actual)Interventional2016-06-27Completed
Assessing the Effect of Periodontal Debridement, Tongue Cleaning and Mouth Rinsing for the Treatment of Oral Malodour [NCT02665780]0 participants (Actual)Interventional2017-10-31Withdrawn(stopped due to funding was not secured)
Clinical Research Study to Evaluate the Effect of Colgate Mouthwashes on Oral Microbiome in Oral Tissue Samples [NCT05270382]24 participants (Anticipated)Interventional2020-02-01Recruiting
Comparison of the Effect of the Preoperative Use of Chlorhexidine, Essential Oil, and Cetylpyridinium Chloride Mouthwashes on Bacterial Contamination During Dental Implant Placement: A Randomized Controlled Clinical Trial [NCT02002442]Phase 230 participants (Actual)Interventional2013-11-30Completed
A Controlled Clinical Study to Determine the Gingivitis Benefit of Flossing [NCT00855933]Phase 460 participants (Actual)Interventional2009-01-31Completed
A Comparison of Mouth Rinse Containing Alcohol-free Chlorhexidine With a Cetylpyridinium Chloride in Periodontal Diseases (A Randomized, Double-blind Clinical Trials) [NCT02756377]Phase 2/Phase 334 participants (Actual)Interventional2014-05-31Completed
A Randomized Controlled Clinical Trial to Evaluate Late First to Mid-Second Trimester Introduction of Advanced Daily Oral Hygiene on Gingivitis and Maternity Outcomes [NCT01549587]746 participants (Actual)Interventional2012-02-29Completed
Effects of Cetylpyridium Chloride (CPC) Based Chewing Gum Plus Tooth Brushing on Plaque Formation and Gingivitis: a Randomized, Double-Blind, Crossover, Placebo-controlled Clinical Trial [NCT03219840]Phase 470 participants (Actual)Interventional2017-10-18Completed
A Randomized, Open, Parallel-group Multicenter Study of Efficacy and Tolerability of a New Medical Device in Gel Formulation (Hyaluronic Acid 0.54%) Versus Calgel® for the Topical Treatment of Teething in Infants [NCT02931357]Phase 354 participants (Actual)Interventional2013-09-30Completed
Double-blind, Randomized, Parallel, Placebo-controlled Clinical Study to Evaluate the Viral Load of SARS-CoV-2 in the Oral Cavity of SARS-CoV-2 Positive Subjects After the Use of a Mouthwash Containing Cetylpyridinium Chloride 0,07% [NCT04757818]118 participants (Actual)Interventional2021-02-17Completed
Mouthwashes as Positive Modulators of Periodontal Response During Orthodontic Treatment: a 6-month Randomized Placebo Controlled Clinical Trial [NCT03179735]Phase 460 participants (Anticipated)Interventional2017-06-01Enrolling by invitation
Avaliação da Carga do vírus SARS-CoV-2 na Cavidade Oral e na Saliva após desinfecção Com soluções Antimicrobianas Orais e dentifrícios. [NCT04537962]202 participants (Actual)Interventional2020-07-14Completed
PILOT CLINICAL TRIAL TO ASSESS THE IMPACT OF ORAL INTERVENTION WITH CETIL PYRIDINIUM CHLORIDE TO REDUCE THE VIRAL LOAD OF SARS-CoV-2 [NCT04820803]80 participants (Actual)Interventional2021-02-03Completed
The Comparative Efficacy of Three Oral Hygiene Multi-component Regimens Encompassing the Use of a Manual Toothbrush, Toothpaste and a Mouthwash in Controlling Established Dental Plaque and Gingivitis. [NCT02193165]Phase 3120 participants (Actual)Interventional2014-07-31Completed
The Clinical Investigation of Colgate Total Toothpaste as Compared to Crest Pro-Health Toothpaste and Crest Pro-Health Mouthwash, and Crest Cavity Protection Toothpaste and Crest Fluoride Mouthwash in Reducing Plaque and Gingivitis: A Six-week Clinical St [NCT02360995]Phase 4129 participants (Actual)Interventional2014-06-30Completed
Evaluation of the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Orally Administered ARMS-I Administered in Healthy Adults, Aged 18-45 Years [NCT03026205]Phase 20 participants (Actual)Interventional2017-01-31Withdrawn
Efficacy of Three Antimicrobial Mouthwashes in Reducing SARS-CoV-2 Viral Load in the Saliva of Patients Diagnosed With COVID-19: A Pilot Study [NCT04723446]54 participants (Actual)Interventional2021-05-19Completed
Clinical Evaluation of Antiseptic Mouth Rinses to Reduce Salivary Viral Load of SARS-CoV-2 in COVID-19 Patients [NCT04707742]160 participants (Actual)Interventional2020-06-15Completed
Clinical Efficacy in Reducing Established Dental Plaque and Gingivitis of a Toothpaste Containing 0.3% Triclosan, 2% Copolymer / Sodium Fluoride and a Manual Toothbrush as Compared to an Oral Hygiene Multi-component Regimen Encompassing the Use of a Manua [NCT02366689]Phase 4179 participants (Actual)Interventional2014-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00855933 (1) [back to overview]Whole Mouth Lobene Modified Gingival Index Between the Brushing Only Group and the Brushing + Flossing Group [30 Days] Units on the MGI Scale
NCT01549587 (6) [back to overview]Change From Baseline in Löe-Silness Gingivitis Index
NCT01549587 (6) [back to overview]Change From Baseline in Löe-Silness Gingivitis Index
NCT01549587 (6) [back to overview]Change From Baseline in Löe-Silness Gingivitis Index
NCT01549587 (6) [back to overview]Gestational Age (Weeks)
NCT01549587 (6) [back to overview]Neonate Birth Weight (Grams)
NCT01549587 (6) [back to overview]Preterm Birth (Gestational Age < 37 Weeks)
NCT02193165 (6) [back to overview]Dental Plaque Scores
NCT02193165 (6) [back to overview]Gingivitis Scores
NCT02193165 (6) [back to overview]Gingivitis Scores
NCT02193165 (6) [back to overview]Gingivitis Scores
NCT02193165 (6) [back to overview]Dental Plaque Scores
NCT02193165 (6) [back to overview]Dental Plaque Scores
NCT02360995 (6) [back to overview]Gingivitis Scores
NCT02360995 (6) [back to overview]Dental Plaque Scores
NCT02360995 (6) [back to overview]Dental Plaque Scores
NCT02360995 (6) [back to overview]Dental Plaque Scores
NCT02360995 (6) [back to overview]Gingivitis Scores
NCT02360995 (6) [back to overview]Gingivitis Scores
NCT02366689 (6) [back to overview]Gingivitis Scores
NCT02366689 (6) [back to overview]Dental Plaque Scores
NCT02366689 (6) [back to overview]Dental Plaque Scores
NCT02366689 (6) [back to overview]Dental Plaque Scores
NCT02366689 (6) [back to overview]Gingivitis Scores
NCT02366689 (6) [back to overview]Gingivitis Scores
NCT03219840 (6) [back to overview]Degree of Plaque as Assessed by the Turesky Modification of the Quigley-Hein Plaque Index
NCT03219840 (6) [back to overview]Degree of Plaque as Assessed by the Turesky Modification of the Quigley-Hein Plaque Index
NCT03219840 (6) [back to overview]Degree of Gingivitis as Assessed by the Gingival Index (GI)
NCT03219840 (6) [back to overview]Degree of Gingivitis as Assessed by the Gingival Index (GI)
NCT03219840 (6) [back to overview]Degree of Gingival Bleeding as Assessed by the Bleeding on Probing (BOP) Index
NCT03219840 (6) [back to overview]Degree of Gingival Bleeding as Assessed by the Bleeding on Probing (BOP) Index
NCT04409873 (3) [back to overview]Change in SARS-CoV-2 Viral Load
NCT04409873 (3) [back to overview]Self-reported Clinical Symptom(s)
NCT04409873 (3) [back to overview]Any Hospitalization(s)

Whole Mouth Lobene Modified Gingival Index Between the Brushing Only Group and the Brushing + Flossing Group [30 Days] Units on the MGI Scale

"A whole-mouth average Lobene Modified Gingival Index was calculated by summing the scores and dividing by the number of sites graded (excludes missing teeth & sites not graded). Whole mouth average can range from 0 (normal) to 4 (severe inflammation).~For each tooth, six gingival areas (distobuccal, buccal, mesiobuccal, mesiolingual, lingual, and distolingual) were scored using the following scale: 0=Normal (Absence of inflammation, 1=Mild inflammation (slight change in color, little change in texture) of any portion of but not the entire marginal or papillary gingival unit, 2=Mild inflammation criteria as above but involving the entire marginal or papillary gingival unit, 3=Moderate inflammation (moderate glazing, redness, edema, and/or hypertrophy) of the marginal or papillary gingival unit, 4=Severe inflammation (marked redness, edema and/or hypertrophy, spontaneous bleeding or ulceration) of the marginal or papillary gingival unit." (NCT00855933)
Timeframe: 4 weeks

Interventionunits on a scale (Mean)
Brushing Only1.84
Brushing + Flossing1.73

[back to top]

Change From Baseline in Löe-Silness Gingivitis Index

"Score Criteria 0 Normal gingiva.~Mild inflammation - slight change in color, slight edema. No bleeding on probing.~Moderate inflammation - redness, edema, and glazing. Bleeding on probing.~Severe inflammation - marked redness, edema. Ulceration. Tendency to spontaneous bleeding." (NCT01549587)
Timeframe: 1 month

Interventionscore on a scale (Least Squares Mean)
Regular Oral Hygiene0.112
Advanced Oral Hygiene Plus Counseling0.125

[back to top]

Change From Baseline in Löe-Silness Gingivitis Index

"Score Criteria 0 Normal gingiva.~Mild inflammation - slight change in color, slight edema. No bleeding on probing.~Moderate inflammation - redness, edema, and glazing. Bleeding on probing.~Severe inflammation - marked redness, edema. Ulceration. Tendency to spontaneous bleeding." (NCT01549587)
Timeframe: 2 months

Interventionscore on a scale (Least Squares Mean)
Regular Oral Hygiene0.124
Advanced Oral Hygiene Plus Counseling0.137

[back to top]

Change From Baseline in Löe-Silness Gingivitis Index

"Score Criteria 0 Normal gingiva.~Mild inflammation - slight change in color, slight edema. No bleeding on probing.~Moderate inflammation - redness, edema, and glazing. Bleeding on probing.~Severe inflammation - marked redness, edema. Ulceration. Tendency to spontaneous bleeding." (NCT01549587)
Timeframe: 3 months

Interventionscore on a scale (Least Squares Mean)
Regular Oral Hygiene0.141
Advanced Oral Hygiene Plus Counseling0.154

[back to top]

Gestational Age (Weeks)

log[42.9-gestational age] (NCT01549587)
Timeframe: At delivery

Interventionlog weeks (Least Squares Mean)
Regular Oral Hygiene1.3988
Advanced Oral Hygiene Plus Counseling1.3271

[back to top]

Neonate Birth Weight (Grams)

(NCT01549587)
Timeframe: At delivery

Interventiongrams (Least Squares Mean)
Regular Oral Hygiene3095.97
Advanced Oral Hygiene Plus Counseling3167.80

[back to top]

Preterm Birth (Gestational Age < 37 Weeks)

(NCT01549587)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Regular Oral Hygiene32
Advanced Oral Hygiene Plus Counseling21

[back to top]

Dental Plaque Scores

Dental Plaque (Quigley-Hein, Turesky Modification Index) Units on a scale 0 to 5 (0 = no plaque, 1 = separate flecks of plaque on the tooth, 2 = a thin continuous band of plaque, 3 = a band of plaque up to one-third of the tooth, 4 = plaque covering up to two thirds of the of the tooth, 5 = plaque covering two-thirds or more of the crown of the tooth) (NCT02193165)
Timeframe: 6 weeks

Interventionunits on a scale (Mean)
Regimen 12.42
Regimen 22.59
Regimen 3 - Control Group3.38

[back to top]

Gingivitis Scores

Gingivitis scale (Loe & Silness Gingival Index) Units on a scale 0 to 3 (0 = no inflammation, 1 = Mild inflammation-slight change in color and little change in texture 2 = Moderate inflammation-moderate glazing, redness, edema and hypertrophy. Tendency to bleed upon probing. 3 = Severe inflammation-marked redness and hypertrophy. Tendency to spontaneous bleeding) (NCT02193165)
Timeframe: Baseline

Interventionunits on a scale (Mean)
Regimen 11.40
Regimen 21.40
Regimen 3 - Control Group1.44

[back to top]

Gingivitis Scores

Gingivitis scale (Loe & Silness Gingival Index) Units on a scale 0 to 3 (0 = no inflammation, 1 = Mild inflammation-slight change in color and little change in texture 2 = Moderate inflammation-moderate glazing, redness, edema and hypertrophy. Tendency to bleed upon probing. 3 = Severe inflammation-marked redness and hypertrophy. Tendency to spontaneous bleeding) (NCT02193165)
Timeframe: 6 weeks

Interventionunits on a scale (Mean)
Regimen 11.03
Regimen 21.21
Regimen 3 - Control Group1.46

[back to top]

Gingivitis Scores

Gingivitis scale (Loe & Silness Gingival Index) Units on a scale 0 to 3 (0 = no inflammation, 1 = Mild inflammation-slight change in color and little change in texture 2 = Moderate inflammation-moderate glazing, redness, edema and hypertrophy. Tendency to bleed upon probing. 3 = Severe inflammation-marked redness and hypertrophy. Tendency to spontaneous bleeding) (NCT02193165)
Timeframe: 4 weeks

Interventionunits on a scale (Mean)
Regimen 11.19
Regimen 21.30
Regimen 3 - Control Group1.44

[back to top]

Dental Plaque Scores

Dental Plaque (Quigley-Hein, Turesky Modification Index) Units on a scale 0 to 5 (0 = no plaque, 1 = separate flecks of plaque on the tooth, 2 = a thin continuous band of plaque, 3 = a band of plaque up to one-third of the tooth, 4 = plaque covering up to two thirds of the of the tooth, 5 = plaque covering two-thirds or more of the crown of the tooth) (NCT02193165)
Timeframe: Baseline

Interventionunits on a scale (Mean)
Regimen 13.33
Regimen 23.19
Regimen 3 - Control Group3.31

[back to top]

Dental Plaque Scores

Dental Plaque (Quigley-Hein, Turesky Modification Index) Units on a scale 0 to 5 (0 = no plaque, 1 = separate flecks of plaque on the tooth, 2 = a thin continuous band of plaque, 3 = a band of plaque up to one-third of the tooth, 4 = plaque covering up to two thirds of the of the tooth, 5 = plaque covering two-thirds or more of the crown of the tooth) (NCT02193165)
Timeframe: 4 weeks

Interventionunits on a scale (Mean)
Regimen 12.78
Regimen 22.79
Regimen 3 - Control Group3.34

[back to top]

Gingivitis Scores

Gingivitis scale (Loe & Silness Gingival Index) Units on a scale 0 to 3 (0 = no inflammation, 1 = Mild inflammation-slight change in color and little change in texture 2 = Moderate inflammation-moderate glazing, redness, edema and hypertrophy. Tendency to bleed upon probing. 3 = Severe inflammation-marked redness and hypertrophy. Tendency to spontaneous bleeding) (NCT02360995)
Timeframe: 4 weeks

Interventionunits on a scale (Mean)
Total Toothpaste1.15
Toothpaste + Mouthwash1.20
Control Group1.30

[back to top]

Dental Plaque Scores

Dental Plaque (Quigley-Hein, Turesky Modification Index) Units on a scale 0 to 5 (0 = no plaque, 1 = separate flecks of plaque on the tooth, 2 = a thin continuous band of plaque, 3 = a band of plaque up to one-third of the tooth, 4 = plaque covering up to two thirds of the of the tooth, 5 = plaque covering two-thirds or more of the crown of the tooth) (NCT02360995)
Timeframe: Baseline

Interventionunits on a scale (Mean)
Total Toothpaste3.91
Toothpaste + Mouthwash3.86
Control Group3.84

[back to top]

Dental Plaque Scores

Dental Plaque (Quigley-Hein, Turesky Modification Index) Units on a scale 0 to 5 (0 = no plaque, 1 = separate flecks of plaque on the tooth, 2 = a thin continuous band of plaque, 3 = a band of plaque up to one-third of the tooth, 4 = plaque covering up to two thirds of the of the tooth, 5 = plaque covering two-thirds or more of the crown of the tooth) (NCT02360995)
Timeframe: 6 weeks

Interventionunits on a scale (Mean)
Total Toothpaste1.05
Toothpaste + Mouthwash1.15
Control Group1.24

[back to top]

Dental Plaque Scores

Dental Plaque (Quigley-Hein, Turesky Modification Index) Units on a scale 0 to 5 (0 = no plaque, 1 = separate flecks of plaque on the tooth, 2 = a thin continuous band of plaque, 3 = a band of plaque up to one-third of the tooth, 4 = plaque covering up to two thirds of the of the tooth, 5 = plaque covering two-thirds or more of the crown of the tooth) (NCT02360995)
Timeframe: 4 weeks

Interventionunits on a scale (Mean)
Total Toothpaste3.42
Toothpaste + Mouthwash3.69
Control Group3.73

[back to top]

Gingivitis Scores

Gingivitis scale (Loe & Silness Gingival Index) Units on a scale 0 to 3 (0 = no inflammation, 1 = Mild inflammation-slight change in color and little change in texture 2 = Moderate inflammation-moderate glazing, redness, edema and hypertrophy. Tendency to bleed upon probing. 3 = Severe inflammation-marked redness and hypertrophy. Tendency to spontaneous bleeding) (NCT02360995)
Timeframe: 6 weeks

Interventionunits on a scale (Mean)
Total Toothpaste1.05
Toothpaste + Mouthwash1.15
Control Group1.24

[back to top]

Gingivitis Scores

Gingivitis scale (Loe & Silness Gingival Index) Units on a scale 0 to 3 (0 = no inflammation, 1 = Mild inflammation-slight change in color and little change in texture 2 = Moderate inflammation-moderate glazing, redness, edema and hypertrophy. Tendency to bleed upon probing. 3 = Severe inflammation-marked redness and hypertrophy. Tendency to spontaneous bleeding) (NCT02360995)
Timeframe: Baseline

Interventionunits on a scale (Mean)
Total Toothpaste1.38
Toothpaste + Mouthwash1.35
Control Group1.41

[back to top]

Gingivitis Scores

Gingivitis scale (Loe & Silness Gingival Index) Units on a scale 0 to 3 (0 = no inflammation, 1 = Mild inflammation-slight change in color and little change in texture 2 = Moderate inflammation-moderate glazing, redness, edema and hypertrophy. Tendency to bleed upon probing. 3 = Severe inflammation-marked redness and hypertrophy. Tendency to spontaneous bleeding) (NCT02366689)
Timeframe: Baseline

Interventionunits on a scale (Mean)
Toothpaste2.18
Toothpaste + Mouthwash2.17
Fluoride Only Toothpaste + Mouthwash2.22

[back to top]

Dental Plaque Scores

Dental Plaque (Quigley-Hein, Turesky Modification Index) Units on a scale 0 to 5 (0 = no plaque, 1 = separate flecks of plaque on the tooth, 2 = a thin continuous band of plaque, 3 = a band of plaque up to one-third of the tooth, 4 = plaque covering up to two thirds of the of the tooth, 5 = plaque covering two-thirds or more of the crown of the tooth) (NCT02366689)
Timeframe: 3 months

Interventionunits on a scale (Mean)
Toothpaste2.26
Toothpaste + Mouthwash2.42
Fluoride Only Toothpaste + Mouthwash2.66

[back to top]

Dental Plaque Scores

Dental Plaque (Quigley-Hein, Turesky Modification Index) Units on a scale 0 to 5 (0 = no plaque, 1 = separate flecks of plaque on the tooth, 2 = a thin continuous band of plaque, 3 = a band of plaque up to one-third of the tooth, 4 = plaque covering up to two thirds of the of the tooth, 5 = plaque covering two-thirds or more of the crown of the tooth) (NCT02366689)
Timeframe: 6 months

Interventionunits on a scale (Mean)
Toothpaste1.84
Toothpaste + Mouthwash1.86
Fluoride Only Toothpaste + Mouthwash2.37

[back to top]

Dental Plaque Scores

Dental Plaque (Quigley-Hein, Turesky Modification Index) Units on a scale 0 to 5 (0 = no plaque, 1 = separate flecks of plaque on the tooth, 2 = a thin continuous band of plaque, 3 = a band of plaque up to one-third of the tooth, 4 = plaque covering up to two thirds of the of the tooth, 5 = plaque covering two-thirds or more of the crown of the tooth) (NCT02366689)
Timeframe: Baseline

Interventionunits on a scale (Mean)
Toothpaste3.33
Toothpaste + Mouthwash3.22
Fluoride Only Toothpaste + Mouthwash3.34

[back to top]

Gingivitis Scores

Gingivitis scale (Loe & Silness Gingival Index) Units on a scale 0 to 3 (0 = no inflammation, 1 = Mild inflammation-slight change in color and little change in texture 2 = Moderate inflammation-moderate glazing, redness, edema and hypertrophy. Tendency to bleed upon probing. 3 = Severe inflammation-marked redness and hypertrophy. Tendency to spontaneous bleeding) (NCT02366689)
Timeframe: 3 months

Interventionunits on a scale (Mean)
Toothpaste1.48
Toothpaste + Mouthwash1.65
Fluoride Only Toothpaste + Mouthwash1.89

[back to top]

Gingivitis Scores

Gingivitis scale (Loe & Silness Gingival Index) Units on a scale 0 to 3 (0 = no inflammation, 1 = Mild inflammation-slight change in color and little change in texture 2 = Moderate inflammation-moderate glazing, redness, edema and hypertrophy. Tendency to bleed upon probing. 3 = Severe inflammation-marked redness and hypertrophy. Tendency to spontaneous bleeding) (NCT02366689)
Timeframe: 6 months

Interventionunits on a scale (Mean)
Toothpaste1.17
Toothpaste + Mouthwash1.18
Fluoride Only Toothpaste + Mouthwash1.85

[back to top]

Degree of Plaque as Assessed by the Turesky Modification of the Quigley-Hein Plaque Index

"Plaque will be assessed using the Turesky Modification of the Quigley-Hein Plaque Index, where a score of 0 to 5 will be assigned to each facial and lingual non-restored surface of all teeth that are present with the exception of third molars at baseline and week 3 of the study, as follows. For each participant, an average of the scores for all teeth is calculated.~0 No plaque~Separate flecks of plaque at the cervical margin of the tooth~A thin continuous band of plaque (up to one mm) at the cervical margin of the tooth~A band of plaque wider than one mm but covering less than one-third of the crown of the tooth~Plaque covering at least one-third but less than two-thirds of the crown of the tooth~Plaque covering two-thirds or more of the crown of the tooth" (NCT03219840)
Timeframe: day 22

Interventionscore on a scale (Mean)
Cetylpyridinium Chloride (CPC) 0.09% + Xylitol Chewing Gum0.36
Xylitol Only Chewing Gum0.35

[back to top]

Degree of Plaque as Assessed by the Turesky Modification of the Quigley-Hein Plaque Index

"Plaque will be assessed using the Turesky Modification of the Quigley-Hein Plaque Index, where a score of 0 to 5 will be assigned to each facial and lingual non-restored surface of all teeth that are present with the exception of third molars at baseline and week 3 of the study, as follows. For each participant, an average of the scores for all teeth is calculated.~0 No plaque~Separate flecks of plaque at the cervical margin of the tooth~A thin continuous band of plaque (up to one mm) at the cervical margin of the tooth~A band of plaque wider than one mm but covering less than one-third of the crown of the tooth~Plaque covering at least one-third but less than two-thirds of the crown of the tooth~Plaque covering two-thirds or more of the crown of the tooth" (NCT03219840)
Timeframe: day 1

Interventionscore on a scale (Mean)
Cetylpyridinium Chloride (CPC) 0.09% + Xylitol Chewing Gum0.41
Xylitol Only Chewing Gum0.43

[back to top]

Degree of Gingivitis as Assessed by the Gingival Index (GI)

"Gingivitis will be assessed using the Gingival Index (GI), where a score of 0 to 3 will be assigned to six teeth, representing six segments of jaws, at baseline and week 3 of the study according to the following criteria. For each participant, an average of the scores for all 6 teeth is calculated.~0 Absence of inflammation.~Mild inflammation - slight change in color and little change in texture.~Moderate inflammation - moderate glazing, redness, edema, and hypertrophy. Bleeding on pressure.~Severe inflammation - marked redness and hypertrophy. Tendency to spontaneous bleeding. Ulceration." (NCT03219840)
Timeframe: day 22

Interventionscore on a scale (Mean)
Cetylpyridinium Chloride (CPC) 0.09% + Xylitol Chewing Gum0.21
Xylitol Only Chewing Gum0.15

[back to top]

Degree of Gingivitis as Assessed by the Gingival Index (GI)

"Gingivitis will be assessed using the Gingival Index (GI), where a score of 0 to 3 will be assigned to six teeth, representing six segments of jaws, at baseline and week 3 of the study according to the following criteria. For each participant, an average of the scores for all 6 teeth is calculated.~0 Absence of inflammation.~Mild inflammation - slight change in color and little change in texture.~Moderate inflammation - moderate glazing, redness, edema, and hypertrophy. Bleeding on pressure.~Severe inflammation - marked redness and hypertrophy. Tendency to spontaneous bleeding. Ulceration." (NCT03219840)
Timeframe: day 1

Interventionscore on a scale (Mean)
Cetylpyridinium Chloride (CPC) 0.09% + Xylitol Chewing Gum0.16
Xylitol Only Chewing Gum0.19

[back to top]

Degree of Gingival Bleeding as Assessed by the Bleeding on Probing (BOP) Index

"Bleeding on probing (BOP) as described in Ainamo & Bay 1975 will be assessed, where each of 4 gingival areas (disto-buccal, midbuccal, mid-lingual, and mesio-lingual) around each tooth will be light probed and scored from 0 to 2 as follows. For each participant, an average of the scores for the 4 gingival areas is calculated.~0 Absence of bleeding after 30 seconds~Bleeding after 30 seconds~Immediate bleeding" (NCT03219840)
Timeframe: day 1

Interventionscore on a scale (Mean)
Cetylpyridinium Chloride (CPC) 0.09% + Xylitol Chewing Gum0.09
Xylitol Only Chewing Gum0.11

[back to top]

Degree of Gingival Bleeding as Assessed by the Bleeding on Probing (BOP) Index

"Bleeding on probing (BOP) as described in Ainamo & Bay 1975 will be assessed, where each of 4 gingival areas (disto-buccal, midbuccal, mid-lingual, and mesio-lingual) around each tooth will be light probed and scored from 0 to 2 as follows. For each participant, an average of the scores for all teeth is calculated, an average of the scores for the 4 gingival areas is calculated.~0 Absence of bleeding after 30 seconds~Bleeding after 30 seconds~Immediate bleeding" (NCT03219840)
Timeframe: day 22

Interventionscore on a scale (Mean)
Cetylpyridinium Chloride (CPC) 0.09% + Xylitol Chewing Gum0.08
Xylitol Only Chewing Gum0.09

[back to top]

Change in SARS-CoV-2 Viral Load

The change in the outcome measure, SARS-CoV-2 viral load, in saliva wash RT-PCR was measured by Cycle Threshold (Ct) value. Ct value refers to the number of cycles it takes for the fluorescent signal generated during the PCR reaction to cross a certain threshold, indicating the presence of the target nucleic acid sequence, here, SARS-CoV-2. The lower the Ct value, the faster the threshold is crossed and the higher the viral load in a biological sample, suggesting a higher concentration of the SARS-CoV-2 virus in that sample. (NCT04409873)
Timeframe: Baseline to 4 weeks

InterventionAbsolute Change in Cycle Threshold (Mean)
Control (Distilled Water)-0.6
Oral-B Mouth Sore (H2O2) Mouthwash-0.4
Crest Pro-Health Multi-Protection (C21H38ClN) Mouthwash0.8
CloSYS (ClO2) Mouthwash-0.4
Listerine Mouthwash-1.4

[back to top]

Self-reported Clinical Symptom(s)

Any self-reported (questionnaire) clinical symptom(s). A symptom checklist included cough, runny nose, scratchy/sore throat, fever, chills, fatigue, muscle ache, shortness of breath, diarrhea/nausea/vomiting, loss of taste/smell, and red /painful eye. (Clinical symptoms were collected at baseline and at 3 months; only problems with the study mouth rinse were collected daily through 4 weeks.) (NCT04409873)
Timeframe: Baseline to 3 months

InterventionParticipants (Count of Participants)
Control (Distilled Water)1
Oral-B Mouth Sore (H2O2) Mouthwash0
Crest Pro-Health Multi-Protection (C21H38ClN) Mouthwash0
CloSYS (ClO2) Mouthwash0
Listerine Mouthwash0

[back to top]

Any Hospitalization(s)

Any hospitalization(s) from baseline to 4 weeks. Hospitalization(s) were collected on adverse event, unanticipated problem, and final disposition forms. (NCT04409873)
Timeframe: Baseline to 4 weeks

InterventionParticipants (Count of Participants)
Control (Distilled Water)0
Oral-B Mouth Sore (H2O2) Mouthwash0
Crest Pro-Health Multi-Protection (C21H38ClN) Mouthwash0
CloSYS (ClO2) Mouthwash0
Listerine Mouthwash0

[back to top]